International Extranodal Lymphoma Study Group
A Swiss-based international group that runs the trials defining treatment of rare extranodal lymphomas, including primary CNS lymphoma and gastric MALT lymphoma.
Founded in 1997 and coordinated from the Oncology Institute of Southern Switzerland in Bellinzona, IELSG focuses on lymphomas arising outside lymph nodes, which no single country can study alone. IELSG32 established the MATRix regimen and consolidation strategies in primary CNS lymphoma, IELSG37 tested omission of mediastinal radiotherapy after PET-negative response in primary mediastinal B-cell lymphoma, and its gastric MALT lymphoma studies defined antibiotic and chlorambucil-rituximab therapy. It collaborates with LYSA, HOVON, the Nordic Lymphoma Group and Australian groups.
- Primary CNS lymphoma (IELSG32, IELSG43)
- Primary mediastinal B-cell lymphoma (IELSG37)
- MALT lymphoma
- Rare extranodal lymphoma registries
Pages like this
not linked directly; found by shared links- InstitutionGerman Lymphoma Alliance
Shares LYSA – The Lymphoma Study Association, HOVON, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- PersonSteven Le Gouill
Shares LYSA – The Lymphoma Study Association, Diffuse large B-cell lymphoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares FDG PET, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TermLugano classification / Ann Arbor staging
Shares FDG PET, Diffuse large B-cell lymphoma.
- CompanyMorphoSys (Novartis)
Shares Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TermDeauville five-point scale
Shares FDG PET, Diffuse large B-cell lymphoma.
- PersonRonald Levy
Shares Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TrialPOLARIX
Shares LYSA – The Lymphoma Study Association, Diffuse large B-cell lymphoma.